open access
COPD 2020 Guidelines — what is new and why?
open access
Abstract
Abstract
Keywords
COPD; GOLD; Guidelines, Update
About this articleTitle
COPD 2020 Guidelines — what is new and why?
Journal
Advances in Respiratory Medicine
Issue
Article type
Letter to the Editor
Pages
39-41
Published online
2020-02-28
DOI
10.5603/ARM.2020.0080
Pubmed
Bibliographic record
Adv Respir Med 2020;88(1):39-41.
Keywords
COPD
GOLD
Guidelines
Update
Authors
Nitesh Gupta
Sumita Agrawal
Shibdas Chakrabarti
Pranav Ish
References (12)- Global Strategy for Diagnosis, Management and Prevention of COPD. The Global Initiative for Chronic Obstructive Lung Diseases (GOLD). 2020 report. Available from: https://goldcopd.org/gold-reports/ [Access: 01.01.2020].
- World Health Organization. Projections of mortality and causes of death, 2016 and 2060. Available from: www.who.int/healthinfo/global_burden_disease/projections/en/ [Access: 14.10.2019].
- Eklöf J, Sørensen R, Ingebrigtsen TS, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2020; 26(2): 227–234.
- Celli BR, Anderson JA, Brook R, et al. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respir Res. 2019; 6(1): e000431.
- Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin — preliminary report. N Engl J Med. 2019 [Epub ahead of print].
- Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018; 52(6).
- Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018; 378(18): 1671–1680.
- Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax. 2019; 74(4): 337–345.
- Devereux G, Cotton S, Fielding S, et al. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. JAMA. 2018; 320(15): 1548–1559.
- Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017; 377(17): 1613–1629.
- Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019; 381(11): 1023–1034.
- Criner GJ, Delage A, Voelker K, et al. Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial. Am J Respir Crit Care Med. 2019; 200(11): 1354–1362.